Financial Performance - The company's revenue for 2024 reached ¥451,874,668.10, representing a 16.22% increase compared to ¥388,794,947.08 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥134,052,917.06, a 35.44% increase from ¥98,973,754.53 in 2023[18]. - The net cash flow from operating activities increased by 43.88% to ¥126,373,559.65 in 2024 from ¥87,829,868.67 in 2023[18]. - Basic earnings per share rose to ¥1.25 in 2024, up 16.82% from ¥1.07 in 2023[18]. - The total assets at the end of 2024 were ¥2,349,619,175.62, a 2.74% increase from ¥2,286,941,939.28 at the end of 2023[18]. - The company achieved operating revenue of 451.87 million yuan, a year-on-year increase of 16.22%, with net profit attributable to shareholders reaching 134.05 million yuan, up 35.44%[52]. - Revenue from peptide synthesis reagents accounted for ¥354,121,700.27, which is 78.37% of total revenue, showing a growth of 17.42% from ¥301,574,821.00 in the previous year[65]. - The company’s gross profit margin improved to 40.28%, with the gross margin for peptide synthesis reagents at 41.55%, reflecting a competitive market environment[56]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2.65 RMB per 10 shares to all shareholders, with no bonus shares issued[5]. - The board of directors has approved the profit distribution plan, reflecting the company's commitment to returning value to shareholders[5]. - The total cash dividend for 2024 is estimated to be CNY 41,719,022.28, with a proposed cash dividend of CNY 2.65 per 10 shares[126]. - The total amount for cash dividends and share buybacks in 2024 is projected to be CNY 83,714,820.96, accounting for 62.45% of the net profit attributable to shareholders[126]. - The company has approved a three-year shareholder dividend return plan for 2024-2026, which was disclosed on June 22, 2024[170]. Research and Development - The company is focused on expanding its market presence and enhancing its research and development capabilities to drive future growth[4]. - The company is actively pursuing new product development and technological advancements to strengthen its competitive position in the market[4]. - R&D expenses rose by 26.40% to ¥35,991,848.34, primarily due to increased personnel costs and depreciation[74]. - The number of R&D personnel increased to 139 in 2024, up 15.83% from 120 in 2023[77]. - The total R&D investment for 2024 amounted to CNY 35,991,848.34, which is a 26.40% increase from the prior year[124]. - The company has a dedicated R&D team of 139 people, accounting for 32.48% of total employees, and has received 11 new invention patents in 2024, bringing the total to 49 patents[107]. Market and Product Development - The company is focusing on high-value products such as liposome and lipid nanoparticle reagents, PROTAC reagents, and nucleotide reagents to meet market demand[28]. - The company has developed a product system primarily based on peptide synthesis reagents, supplemented by general molecular building blocks and protein reagents[28]. - The company is actively expanding its product pipeline to support global pharmaceutical research and production enterprises[28]. - The company has established a leading position in the peptide synthesis reagent industry, providing over 160 innovative and high-quality products[34]. - The company is focusing on the development of new peptide synthesis reagents, including high-reactivity and low-toxicity derivatives, which are anticipated to have a strong market outlook[30]. - The company has developed over 60 types of general-purpose molecular building blocks, with more than 800 specific products available, indicating a strong product line expansion[36]. Governance and Compliance - The financial report emphasizes the importance of accurate and complete financial disclosures, with the board and management taking legal responsibility for the report's content[4]. - The report outlines the company's governance structure and its commitment to environmental and social responsibilities[5]. - The company has established a governance structure to enhance operational efficiency and ensure compliance with regulations[109]. - The company emphasizes transparency and adheres to regulations for information disclosure, ensuring all shareholders have equal access to information[131]. - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management, enhancing governance[132]. Risk Management - The company highlights potential risks including capacity shortages, performance fluctuations, and loss of core technical personnel, which could impact future development[4]. - The company emphasizes the need for investors to understand the differences between plans, forecasts, and commitments, highlighting the inherent risks involved[4]. - The company recognizes the risk of losing core technical personnel and is focused on providing a supportive environment to retain talent and maintain competitive advantage[117]. - The company is aware of the risk of insufficient R&D innovation and aims to recruit top talent and align with industry trends to sustain its competitive edge[118]. Environmental Responsibility - The company is committed to complying with environmental regulations and has invested in environmental protection measures to mitigate operational risks[120]. - The company has implemented strict compliance with environmental regulations, including the Comprehensive Discharge Standards for Wastewater and Air Pollutants[183]. - The company has invested a total of 4,121,100 CNY in environmental protection equipment and projects in 2024, with operational expenses amounting to 1,706,270 CNY for environmental protection tax[188]. - The company has established an emergency response plan for environmental incidents, which has been filed with local ecological authorities[188]. Shareholder Engagement - The annual shareholders' meeting had a participation rate of 71.36% on May 10, 2024, indicating strong shareholder engagement[136]. - The company has a dedicated investor relations manager to facilitate communication and enhance transparency with investors[131]. - The company actively respects and maintains the rights of stakeholders, balancing interests among shareholders, employees, and society[132]. Strategic Partnerships and Future Outlook - The company plans to establish a wholly-owned subsidiary, Highfine Biotech GmbH, in Germany by January 2025 to enhance its presence in the European market[54]. - The company is actively exploring opportunities for mergers and acquisitions to strengthen its competitive position in the market[142]. - Future outlook indicates a commitment to technological innovation and market expansion, aiming for a 15% increase in revenue next fiscal year[140].
昊帆生物(301393) - 2024 Q4 - 年度财报